The US tariff threat on certain medicines has caused Indian pharma stocks to decline, with notable drops seen in Biocon, Sun Pharma, Glenmark, Aurobindo, and Ipca Labs by 4-5%. The Nifty Pharma index fell by 3.8% due to these concerns about reshoring production.

Motilal Oswal's Sneha Poddar suggests investing in five stocks, such as ICICI Bank, Max Financial, Tata Power, Aurobindo Pharma, and IPCA Labs, due to their promising upside potential of up to 48%. These selections are driven by their strong growth, profitability, and operational enhancements.

Ipca Labs' stock appears to be gaining momentum, with strong technical signals suggesting a shift towards a bullish trend. Key metrics such as moving averages, Bollinger Bands, and MACD are all pointing positively, indicating potential growth in the near future.